Meeting
2023 ASCO Annual Meeting
Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer.
Authors
Biagio Ricciuti
Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Boston, MA
Biagio Ricciuti , Joao Victor Machado Alessi , Xinan Wang , Giuseppe Lamberti , Federica Pecci , Alessandro Di Federico , Malini Marion Gandhi , Lynette M. Sholl , Chiara Ambrogio , Mark M. Awad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9118)
DOI
10.1200/JCO.2023.41.16_suppl.9118
Abstract #
9118
Poster Bd #
106
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).
First Author: Robert Hsu
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.
First Author: Heng Tan
Poster
2022 ASCO Annual Meeting
Three-year outcomes and correlative analyses in patients with non–small cell lung cancer (NSCLC) and a very high PD-L1 tumor proportion score (TPS) ≥ 90% treated with first-line pembrolizumab.
First Author: Biagio Ricciuti
Poster
2022 ASCO Annual Meeting
Comprehensive genomic and transcriptomic characterization of small bowel adenocarcinoma.
First Author: Karan Pandya